I have written a function to calculate the Runge-Kutta numerical approximation of the differential equation dy/dt = -2ty^2 w/ initial conditions y(0)=1 from ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability.

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma ...

--Recursion Pharmaceuticals, Inc., ... today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share.

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds ...

Dataclass transforms. Since Python 3.7, dataclasses have made it easier to define classes that followed common patterns for creating properties based on their initialization parameters. But there ...

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (RXRX) (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to ...

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 monthsPlan to initiate dosing ...

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor ...